Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiroxostat vs allopurinol in gout with hyperuricemia (Phase 3, China)
ChiCTR2600127737Phase 3Not yet recruiting
- Sponsor
- Xiang'an Hospital of Xiamen University
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of topiroxostat in gout and hyperuricemia (2 arms), sponsored by Xiang'an Hospital of Xiamen University. Primary endpoint: Target serum uric acid achievement at Week 24. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
topiroxostat
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on ChiCTR2600127737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127737.